Targeting the Resistance in Multiple Myeloma†
AbstractMultiple myeloma is a hematological cancer characterized by the clonal proliferation of malignant plasma cells in the bone marrow. That disease has a rather low incidence but displays a high rate of relapse and resistance to conventional therapies. It is therefore necessary to find new therapeutic strategies to overcome this resistance, which is partly attributed to a subpopulation of cells known as cancer stem cells. Withanolides and HDAC6 selective inhibitors were identified as promising compounds in various resistant multiple myeloma models.
Share & Cite This Article
Freitas, M.; Issa, M.E.; Cuendet, M. Targeting the Resistance in Multiple Myeloma. Proceedings 2019, 11, 3.
Freitas M, Issa ME, Cuendet M. Targeting the Resistance in Multiple Myeloma. Proceedings. 2019; 11(1):3.Chicago/Turabian Style
Freitas, Micaela; Issa, Mark E.; Cuendet, Muriel. 2019. "Targeting the Resistance in Multiple Myeloma." Proceedings 11, no. 1: 3.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.